The Chosun Ilbo on MSN

GC Biopharma expands Alyglo indications to pediatric patients

GC Biopharma is accelerating its global market strategy, centered on its flagship product “Alyglo.” The company aims to build a mid- to long-term growth foundation by expanding the scope of ...
Fierce Pharma

Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech

After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
The Manila Times

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 ...
The American Journal of Managed Care

Overcoming Barriers and Future Integration of Subcutaneous Therapies in Lung Cancer

In the final episode, Overcoming Barriers and Future Integration of Subcutaneous Therapies in Lung Cancer, the panelists explored the following critical questions: What are the ke ...
StockStory.org on MSN

Unpacking Q4 earnings: Halozyme Therapeutics (NASDAQ:HALO) in the context of other therapeutics stocks

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Plasma Fractionation Market to Reach USD 51.06 Billion by 2032, Driven by Rising Demand for Immunoglobulins and Growing Prevalence of Immune Disorders | MarkNtel Advisors

Regionally, North America leads the Global Plasma Fractionation Market, accounting for approximately 54% of the total market share in 2026. The region's dominance is supported by well-established plas ...
Pharmabiz

Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma

Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma: Tokyo Tuesday, March 24, 2026, 11: ...

New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress

BioArctic's AB (publ) (STOCKHOLM: BIOA B ) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and ...

LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real--World Evidence, Long--Term Outcomes and Patient Experience Across Multiple Dermatological Conditions

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...
TMCnet

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...
The Manila Times

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics Holdings, Inc. ('Rani Therapeutics” or 'Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it ...
Drug Store News

Celltrion introduces Avtozma SC

Avtozma is among the first wave of tocilizumab biosimilars with both intravenous and subcutaneous formulations approved and commercially available in the United States.